FAKTOR OPTIONSSCHEIN - EMERGENT BIOSOLUTIONS Stock

Certificat

DE000GQ9QN87

Real-time BOERSE MUENCHEN 02:26:10 2024-07-01 pm EDT
5.68 EUR +9.02% Intraday chart for FAKTOR OPTIONSSCHEIN - EMERGENT BIOSOLUTIONS
Date Price Change
24-07-01 5.68 +9.02%
24-06-28 5.21 -19.97%

Real-time BOERSE MUENCHEN

Last update July 01, 2024 at 02:26 pm EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying EMERGENT BIOSOLUTIONS INC.
Issuer Goldman Sachs
WKN GQ9QN8
ISINDE000GQ9QN87
Date issued 2024-06-26
Strike 7.502 $
Maturity Unlimited
Parity 0.1 : 1
Emission price 8.88
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 14.6
Lowest since issue 4.28
Spread 0.07
Spread %1.19%

Company Profile

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Sector
-
More about the company

Ratings for Emergent BioSolutions Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Emergent BioSolutions Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.82 USD
Average target price
8 USD
Spread / Average Target
+17.30%
Consensus